<p>Price T Rowe Associates Inc. MD 在第一季度削減了其在 Pacira BioSciences, Inc.（NASDAQ: PCRX - Free Report）的持股比例，根據其最近向證券交易委員會披露的信息，持股比例下降了 17.8%。該機構投資者在本季度出售了 71,733 股股票後，擁有公司股票的 332,020 股。Price T Rowe Associates Inc. MD 在最近季度結束時擁有 Pacira BioSciences 價值 970.3 萬美元的股份，佔比 0.71%。</p>
<p>獲取 <strong>Pacira BioSciences</strong> 警報：</p>
<p>許多其他對沖基金最近也買入並出售了該公司的股票。Vanguard Group Inc.在第一季度將其對 Pacira BioSciences 的持股比例提高了 0.3%。Vanguard Group Inc.現在擁有公司股票 5,113,384 股，價值 1.49413 億美元，比上一季度增加了 14,960 股。Frontier Capital Management Co. LLC 在第四季度將其對 Pacira BioSciences 的持倉比例提高了 15.8%。Frontier Capital Management Co. LLC 現在擁有公司股票 2,084,542 股，價值 7,033.2 萬美元，比上一季度增加了 285,045 股。Dimensional Fund Advisors LP 在第四季度將其對 Pacira BioSciences 的持倉比例提高了 1.3%。Dimensional Fund Advisors LP 現在擁有公司股票 1,411,767 股，價值 4,763.3 萬美元，比上一季度增加了 17,949 股。Vestal Point Capital LP 在第四季度購入了 Pacira BioSciences 的新股份，價值約 4,048.8 萬美元。最後，Clearbridge Investments LLC 在第一季度將其對 Pacira BioSciences 的持倉比例提高了 2.3%。Clearbridge Investments LLC 現在擁有公司股票 1,172,150 股，價值 3,425 萬美元，比上一季度增加了 26,463 股。99.73% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些研究公司最近發佈了關於 PCRX 的報告。加拿大皇家銀行將 Pacira BioSciences 的目標股價從 42.00 美元降至 37.00 美元，並在週三的研究報告中為該公司設定了 “表現優異” 的評級。雷蒙德詹姆斯將 Pacira BioSciences 的目標股價從 41.00 美元降至 37.00 美元，並在週三的研究報告中為該公司設定了 “表現優異” 的評級。Needham &amp; Company LLC 重申了對 Pacira BioSciences 的 “買入” 評級，並設定了 43.00 美元的目標股價。HC Wainwright 重申了對 Pacira BioSciences 的 “買入” 評級，並在 7 月 2 日星期二的一份報告中設定了 57.00 美元的目標股價。最後，Truist Financial 將 Pacira BioSciences 的目標股價從 45.00 美元降至 30.00 美元，並在 7 月 25 日星期四的一份報告中為該股設定了 “買入” 評級。一位分析師對該股票進行了持有評級，八位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該股目前的平均評級為 “買入”，平均目標股價為 41.44 美元。</p>
<p><strong>查看我們關於 Pacira BioSciences 的最新研究報告</strong></p>
<h2>Pacira BioSciences 內部買賣情況</h2>
<p>據悉，Pacira BioSciences 的另一內部消息顯示，內部人士 Jonathan Slonin 於 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均價格出售，交易總額為 143,192.84 美元。交易完成後，該內部人士現在持有公司 44,569 股股票，價值 1,273,336.33 美元。該交易已在向 SEC 提交的文件中披露，可在 SEC 網站上查看。另外，首席運營官 Daryl Gaugler 於 6 月 13 日星期四出售了 1,000 股股票。股票以 28.38 美元的平均價格出售，交易總額為 28,380.00 美元。交易完成後，該首席運營官現在直接持有公司 116,040 股股票，價值 3,293,215.20 美元。該交易已在提交給證券交易委員會的文件中披露，可通過此超鏈接訪問。此外，內部人士 Jonathan Slonin 於 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均價格出售，交易總額為 143,192.84 美元。交易完成後，該內部人士現在直接持有公司 44,569 股股票，價值 1,273,336.33 美元。此次交易的披露信息可在此處找到。內部人士在過去 90 天內已出售了總價值 621,118 美元的 22,095 股公司股票。內部人士持有公司股票的比例為 6.40%。</p>
<h2>Pacira BioSciences 股價上漲 2.5%</h2>
<p>PCRX 股票週五開盤價為 21.26 美元。Pacira BioSciences, Inc.的 12 個月最低價為 19.34 美元，最高價為 40.16 美元。該公司的速動比率為 4.78，流動比率為 6.82，負債權益比為 0.67。公司的 50 天移動平均價格為 25.03 美元，200 天移動平均價格為 27.83 美元。該公司的市值為 9.8072 億美元，市盈率為 14.87，貝塔係數為 0.88。</p>
<p>Pacira BioSciences（NASDAQ: PCRX - Get Free Report）最近公佈了截至 5 月 7 日星期二的季度收益結果。公司報告的每股收益為 0.42 美元，低於每股 0.46 美元的共識預期。Pacira BioSciences 的淨利潤率為 9.21%，淨資產收益率為 13.22%。該季度公司的營收為 1.6712 億美元，而分析師預計為 1.6543 億美元。股票分析師預測，Pacira BioSciences, Inc.今年將實現 2.13 美元的每股收益。</p>
<h2>Pacira BioSciences 公司簡介（免費報告）</h2>
<p>Pacira BioSciences, Inc 從事開發、製造、營銷、分銷和銷售非阿片類疼痛管理和再生健康解決方案給美國的醫療從業者。該公司提供 EXPAREL，一種布比卡因脂質體注射懸液；ZILRETTA，一種曲安奈德緩釋注射懸液；以及 iovera 系統，一種非阿片類手持式冷凍鎮痛設備，用於向靶神經產生受控的冷温度劑量。</p>
<h2>推薦故事</h2>
<ul>
<li>五支我們比 Pacira BioSciences 更喜歡的股票</li>
<li>為什麼這些公司被認為是藍籌股？</li>
<li>Hims &amp; Hers 股價下跌，因 DexCom 擔憂：分析師預測反彈</li>
<li>投資中降級意味着什麼？</li>
<li>Snap 季度營收指引不及預期，股價暴跌</li>
<li>資產配置：成功投資組合的關鍵。您是否關注您的資產配置？</li>
<li>英特爾在糟糕的財報後市值蒸發四分之一</li>
</ul>
<p><strong>想看看其他對 PCRX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Pacira BioSciences, Inc. (NASDAQ:PCRX - 免費報告) 的最新 13F 申報和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 羅根和卡爾森警告：當心數字貨幣的威脅（來自 Priority Gold）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3"/></p>
<h2>現在是否值得投資$1,000 在 Pacira BioSciences？</h2>
<p>在考慮 Pacira BioSciences 之前，您應該聽聽這個。</p>
<p>MarketBeat 追蹤華爾街頂尖和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂尖分析師悄悄告訴客户現在購買的股票...而 Pacira BioSciences 不在名單上。</p>
<p>雖然 Pacira BioSciences 目前在分析師中有 “中等買入” 評級，但頂尖分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

Pacira制藥

<p>Price T Rowe Associates Inc. MD 在第一季度減持 Pacira BioSciences 17.8% 的持股比例。其他對沖基金也買入和賣出了該公司的股票。華爾街分析師預測該公司將有增長，平均目標股價為 41.44 美元。內部人士在過去 90 天內共出售了 22,095 股價值 621,118 美元的公司股票</p>

<p>Price T Rowe Associates Inc. MD cut its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 17.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 332,020 shares of the company's stock after selling 71,733 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.71% of Pacira BioSciences worth $9,703,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Price T Rowe Associates Inc. MD 在第一季度削減了其在 Pacira BioSciences, Inc.（NASDAQ: PCRX - Free Report）的持股比例，根據其最近向證券交易委員會披露的信息，持股比例下降了 17.8%。該機構投資者在本季度出售了 71,733 股股票後，擁有公司股票的 332,020 股。Price T Rowe Associates Inc. MD 在最近季度結束時擁有 Pacira BioSciences 價值 970.3 萬美元的股份，佔比 0.71%。</p>
</div><p>Get <strong>Pacira BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Pacira BioSciences</strong> 警報：</p>
</div><p>A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in Pacira BioSciences by 0.3% during the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company's stock valued at $149,413,000 after buying an additional 14,960 shares in the last quarter. Frontier Capital Management Co. LLC lifted its position in shares of Pacira BioSciences by 15.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 2,084,542 shares of the company's stock worth $70,332,000 after purchasing an additional 285,045 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Pacira BioSciences by 1.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,411,767 shares of the company's stock worth $47,633,000 after purchasing an additional 17,949 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Pacira BioSciences in the fourth quarter worth approximately $40,488,000. Finally, Clearbridge Investments LLC lifted its position in shares of Pacira BioSciences by 2.3% in the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company's stock worth $34,250,000 after purchasing an additional 26,463 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>許多其他對沖基金最近也買入並出售了該公司的股票。Vanguard Group Inc.在第一季度將其對 Pacira BioSciences 的持股比例提高了 0.3%。Vanguard Group Inc.現在擁有公司股票 5,113,384 股，價值 1.49413 億美元，比上一季度增加了 14,960 股。Frontier Capital Management Co. LLC 在第四季度將其對 Pacira BioSciences 的持倉比例提高了 15.8%。Frontier Capital Management Co. LLC 現在擁有公司股票 2,084,542 股，價值 7,033.2 萬美元，比上一季度增加了 285,045 股。Dimensional Fund Advisors LP 在第四季度將其對 Pacira BioSciences 的持倉比例提高了 1.3%。Dimensional Fund Advisors LP 現在擁有公司股票 1,411,767 股，價值 4,763.3 萬美元，比上一季度增加了 17,949 股。Vestal Point Capital LP 在第四季度購入了 Pacira BioSciences 的新股份，價值約 4,048.8 萬美元。最後，Clearbridge Investments LLC 在第一季度將其對 Pacira BioSciences 的持倉比例提高了 2.3%。Clearbridge Investments LLC 現在擁有公司股票 1,172,150 股，價值 3,425 萬美元，比上一季度增加了 26,463 股。99.73% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research firms have recently issued reports on PCRX. Royal Bank of Canada reduced their price target on shares of Pacira BioSciences from $42.00 to $37.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Raymond James reduced their price target on shares of Pacira BioSciences from $41.00 to $37.00 and set an &#34;outperform&#34; rating for the company in a research report on Wednesday. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $43.00 price target on shares of Pacira BioSciences in a research report on Wednesday. HC Wainwright restated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Pacira BioSciences in a report on Tuesday, July 2nd. Finally, Truist Financial dropped their price objective on Pacira BioSciences from $45.00 to $30.00 and set a &#34;buy&#34; rating on the stock in a report on Thursday, July 25th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Buy&#34; and an average target price of $41.44.</p>
<div class="lb-trans"><p>一些研究公司最近發佈了關於 PCRX 的報告。加拿大皇家銀行將 Pacira BioSciences 的目標股價從 42.00 美元降至 37.00 美元，並在週三的研究報告中為該公司設定了 “表現優異” 的評級。雷蒙德詹姆斯將 Pacira BioSciences 的目標股價從 41.00 美元降至 37.00 美元，並在週三的研究報告中為該公司設定了 “表現優異” 的評級。Needham &amp; Company LLC 重申了對 Pacira BioSciences 的 “買入” 評級，並設定了 43.00 美元的目標股價。HC Wainwright 重申了對 Pacira BioSciences 的 “買入” 評級，並在 7 月 2 日星期二的一份報告中設定了 57.00 美元的目標股價。最後，Truist Financial 將 Pacira BioSciences 的目標股價從 45.00 美元降至 30.00 美元，並在 7 月 25 日星期四的一份報告中為該股設定了 “買入” 評級。一位分析師對該股票進行了持有評級，八位分析師給予了買入評級，一位分析師給予了強烈買入評級。根據 MarketBeat 的數據，該股目前的平均評級為 “買入”，平均目標股價為 41.44 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Pacira BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Pacira BioSciences 的最新研究報告</strong></p>
</div><h2>Insider Buying and Selling at Pacira BioSciences</h2>
<div class="lb-trans"><h2>Pacira BioSciences 內部買賣情況</h2>
</div><p>In other Pacira BioSciences news, insider Jonathan Slonin sold 5,012 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $28.57, for a total transaction of $143,192.84. Following the transaction, the insider now owns 44,569 shares in the company, valued at $1,273,336.33. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, COO Daryl Gaugler sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $28.38, for a total value of $28,380.00. Following the completion of the sale, the chief operating officer now directly owns 116,040 shares of the company's stock, valued at $3,293,215.20. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Slonin sold 5,012 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $28.57, for a total value of $143,192.84. Following the completion of the sale, the insider now directly owns 44,569 shares of the company's stock, valued at $1,273,336.33. The disclosure for this sale can be found here. Insiders have sold a total of 22,095 shares of company stock worth $621,118 over the last 90 days. Insiders own 6.40% of the company's stock.</p>
<div class="lb-trans"><p>據悉，Pacira BioSciences 的另一內部消息顯示，內部人士 Jonathan Slonin 於 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均價格出售，交易總額為 143,192.84 美元。交易完成後，該內部人士現在持有公司 44,569 股股票，價值 1,273,336.33 美元。該交易已在向 SEC 提交的文件中披露，可在 SEC 網站上查看。另外，首席運營官 Daryl Gaugler 於 6 月 13 日星期四出售了 1,000 股股票。股票以 28.38 美元的平均價格出售，交易總額為 28,380.00 美元。交易完成後，該首席運營官現在直接持有公司 116,040 股股票，價值 3,293,215.20 美元。該交易已在提交給證券交易委員會的文件中披露，可通過此超鏈接訪問。此外，內部人士 Jonathan Slonin 於 6 月 11 日星期二出售了 5,012 股股票。股票以 28.57 美元的平均價格出售，交易總額為 143,192.84 美元。交易完成後，該內部人士現在直接持有公司 44,569 股股票，價值 1,273,336.33 美元。此次交易的披露信息可在此處找到。內部人士在過去 90 天內已出售了總價值 621,118 美元的 22,095 股公司股票。內部人士持有公司股票的比例為 6.40%。</p>
</div><h2>Pacira BioSciences Trading Up 2.5 %</h2>
<div class="lb-trans"><h2>Pacira BioSciences 股價上漲 2.5%</h2>
</div><p>Shares of PCRX stock opened at $21.26 on Friday. Pacira BioSciences, Inc. has a 12 month low of $19.34 and a 12 month high of $40.16. The company has a quick ratio of 4.78, a current ratio of 6.82 and a debt-to-equity ratio of 0.67. The business's 50 day moving average is $25.03 and its two-hundred day moving average is $27.83. The company has a market cap of $980.72 million, a PE ratio of 14.87 and a beta of 0.88.</p>
<div class="lb-trans"><p>PCRX 股票週五開盤價為 21.26 美元。Pacira BioSciences, Inc.的 12 個月最低價為 19.34 美元，最高價為 40.16 美元。該公司的速動比率為 4.78，流動比率為 6.82，負債權益比為 0.67。公司的 50 天移動平均價格為 25.03 美元，200 天移動平均價格為 27.83 美元。該公司的市值為 9.8072 億美元，市盈率為 14.87，貝塔係數為 0.88。</p>
</div><p>Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. The company had revenue of $167.12 million for the quarter, compared to analyst estimates of $165.43 million. Equities analysts predict that Pacira BioSciences, Inc. will post 2.13 EPS for the current year.</p>
<div class="lb-trans"><p>Pacira BioSciences（NASDAQ: PCRX - Get Free Report）最近公佈了截至 5 月 7 日星期二的季度收益結果。公司報告的每股收益為 0.42 美元，低於每股 0.46 美元的共識預期。Pacira BioSciences 的淨利潤率為 9.21%，淨資產收益率為 13.22%。該季度公司的營收為 1.6712 億美元，而分析師預計為 1.6543 億美元。股票分析師預測，Pacira BioSciences, Inc.今年將實現 2.13 美元的每股收益。</p>
</div><h2>Pacira BioSciences Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Pacira BioSciences 公司簡介（免費報告）</h2>
</div><p>Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.</p>
<div class="lb-trans"><p>Pacira BioSciences, Inc 從事開發、製造、營銷、分銷和銷售非阿片類疼痛管理和再生健康解決方案給美國的醫療從業者。該公司提供 EXPAREL，一種布比卡因脂質體注射懸液；ZILRETTA，一種曲安奈德緩釋注射懸液；以及 iovera 系統，一種非阿片類手持式冷凍鎮痛設備，用於向靶神經產生受控的冷温度劑量。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Pacira BioSciences</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Hims &amp; Hers Stock Falls on DexCom Fears: Analysts Predict Rally</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Snap's Stock Plummets on Q2 Revenue Guidance Shortfall</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Intel Loses a Quarter of Its Value After Horrible Earnings Report</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>五支我們比 Pacira BioSciences 更喜歡的股票</li>
<li>為什麼這些公司被認為是藍籌股？</li>
<li>Hims &amp; Hers 股價下跌，因 DexCom 擔憂：分析師預測反彈</li>
<li>投資中降級意味着什麼？</li>
<li>Snap 季度營收指引不及預期，股價暴跌</li>
<li>資產配置：成功投資組合的關鍵。您是否關注您的資產配置？</li>
<li>英特爾在糟糕的財報後市值蒸發四分之一</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PCRX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 PCRX 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 Pacira BioSciences, Inc. (NASDAQ:PCRX - 免費報告) 的最新 13F 申報和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UENSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關本故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Rogan and Carlson Warning: Beware the Digital Currency Menace (From Priority Gold)(Ad)</p>
<div class="lb-trans"><p>→ 羅根和卡爾森警告：當心數字貨幣的威脅（來自 Priority Gold）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04OTQ3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8947&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Pacira BioSciences right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Pacira BioSciences？</h2>
</div><p>Before you consider Pacira BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Pacira BioSciences 之前，您應該聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂尖和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂尖分析師悄悄告訴客户現在購買的股票...而 Pacira BioSciences 不在名單上。</p>
</div><p>While Pacira BioSciences currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Pacira BioSciences 目前在分析師中有 “中等買入” 評級，但頂尖分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

Pacira BioSciences, Inc.（納斯達克代碼：PCRX）的持倉被 Price T Rowe Associates Inc. MD 減少